Kamada Ltd. (NASDAQ:KMDA) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for Kamada on Accelerated Trial Prospects and Strong Financial Performance
Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript
Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript
Kamada Ltd. Reports Strong Growth and Raises Guidance
Kamada Boosts FY24 Revenue Guidance From $156M-$160M To $158M-$162M, Est $158.22M
Kamada also increased adjusted EBITDA guidance to $28 million to $32 million from the initial guidance of $27 million to $30 million."Importantly, we continue to pursue compelling new business develop
Kamada Sees 2024 Adj Ebitda in $28M to $32M Range >KMDA.TA.TV
Kamada Sees 2024 Adj Ebitda in $28M to $32M Range >KMDA.TA.TV
Express News | Kamada Increases 2024 Adj Ebitda Forecast to $28M-$32M
Kamada Sees 2024 Rev $158M-$162M >KMDA.TA.TV
Kamada Sees 2024 Rev $158M-$162M >KMDA.TA.TV
Kamada 1Q Rev $37.7M >KMDA.TA.TV
Kamada 1Q Rev $37.7M >KMDA.TA.TV
Kamada Raises 2024 Guidance >KMDA.TA.TV
Kamada Raises 2024 Guidance >KMDA.TA.TV
Kamada 1Q EPS 4c >KMDA.TA.TV
Kamada 1Q EPS 4c >KMDA.TA.TV
Kamada | 6-K: Report of foreign private issuer (related to financial reporting)
Kamada Q1 2024 GAAP EPS $0.04 Misses $0.06 Estimate, Sales $37.736M Miss $38.007M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. The company reported quarterly sales of $37.736 million whic
Press Release: Kamada Reports Strong First Quarter 2024 Financial Results With Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance -- Revenues for First
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for
Earnings Call: Kamada Ltd. Sees Growth and Optimistic 2024 Outlook
Express News | HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Kamada Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 80.62% HC Wainwright & Co. → $11 Reiterates Buy → Buy 11/14/2023 80.62% HC Wainwright & Co. → $
Strategic Partnerships and Product Portfolio Expansion Poise Kamada for Robust Growth
Earnings Call Summary | Kamada(KMDA.US) Q4 2023 Earnings Conference
The following is a summary of the Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript:Financial Performance:Kamada Ltd. reported 2023 revenue of $142.5 million, marking a 10% year-over-year increase.
No Data